IGF-1, or insulin-like growth factor 1, is a hormone that circulates in your blood at levels shaped by genetics, diet, growth hormone output, and liver function. When those levels run high, the consequences depend heavily on the cause and the degree. A pituitary tumor driving relentless growth hormone secretion creates a very different health picture than a diet rich in dairy protein nudging IGF-1 upward by a modest percentage. The hormone sits at the center of a surprising number of bodily systems, from bone density and muscle mass to cancer risk and cognitive health, and the relationship between IGF-1 and disease is often U-shaped rather than linear, meaning both too little and too much can be harmful.
How the Body Regulates IGF-1
Most of the IGF-1 in your bloodstream comes from the liver, which produces it in response to growth hormone released by the pituitary gland. Growth hormone pulses throughout the day, peaking during deep sleep and after exercise, and the liver converts those pulses into a steadier supply of IGF-1. The relationship between growth hormone, IGF-1, and insulin is tightly interwoven: insulin levels influence how much IGF-1 the liver produces, and IGF-1 in turn feeds back to suppress further growth hormone release. Disruptions anywhere in this loop, whether from a tumor, liver disease, or metabolic syndrome, can push IGF-1 out of its normal range.1Europe PMC. The Fascinating Interplay between Growth Hormone, Insulin-Like Growth Factor-1, and Insulin
Once in the bloodstream, IGF-1 does not travel alone. It binds to a family of carrier proteins called IGF binding proteins (IGFBPs), which regulate how much free IGF-1 is available to enter tissues and activate receptors. IGFBP-3 is the most abundant of these carriers, and the ratio of IGF-1 to IGFBP-3 often matters more clinically than the total IGF-1 number by itself. The binding proteins also have their own signaling roles independent of IGF-1, which complicates the picture further.2PubMed Central. The IGF-I regulatory system and its impact on skeletal and energy homeostasis
Acromegaly and Other Pathological Causes
The most dramatic cause of persistently high IGF-1 is acromegaly, a rare condition caused by a growth hormone-secreting pituitary tumor. These tumors are almost always benign but can be locally invasive and difficult to fully control with treatment.3The Lancet Diabetes & Endocrinology. Acromegaly The relentless excess of growth hormone drives IGF-1 levels far above normal, producing a broad set of complications that span the cardiovascular, respiratory, metabolic, musculoskeletal, and neurological systems. Joint pain, enlarged hands and feet, thickened facial features, and sleep apnea are classic signs. Some of these changes may not fully reverse even after the tumor is treated.4Endocrinology and Metabolism. Insulin-Like Growth Factor 1 as a Pillar in Acromegaly: From Diagnosis to Long-Term Management
Outside of acromegaly, moderately elevated IGF-1 can appear in people with high protein intake, obesity (particularly in the earlier stages before liver function is compromised), puberty, and pregnancy. Certain genetic variants also predispose individuals to higher baseline levels. The clinical significance of these milder elevations is an area of active debate, especially when the levels fall in the upper-normal range rather than clearly above it.
Dietary and Lifestyle Drivers
What you eat has a measurable effect on circulating IGF-1. Total protein intake is the most consistent dietary predictor, and dairy protein appears to have an outsized influence. A large study found that milk protein and yogurt protein were both positively associated with higher circulating IGF-1, while cheese protein showed no clear association.5PubMed Central. Associations of circulating insulin-like growth factor-I with intake of dietary proteins and other macronutrients In the Women’s Health Initiative, an increase of three daily servings of milk was associated with roughly an 18% rise in free IGF-1.6PubMed Central. Associations of Serum Insulin-like Growth Factor (IGF-I) and IGFBP-3 Levels Biomarker-Calibrated Protein, Dairy, and Milk Intake in the Women’s Health Initiative A smaller controlled feeding study found that a high-protein condition raised 24-hour IGF-1 by about 17% compared to baseline.7PubMed Central. Exercise, Dietary Protein, and Combined Effect on IGF-1
Glycemic load also plays a role. In a controlled feeding trial, people eating a low-glycemic-load diet for 28 days had about 4% lower fasting IGF-1 concentrations and a lower IGF-1 to IGFBP-3 ratio compared to those on a high-glycemic-load diet.8PubMed Central. Glycemic load effect on fasting and post-prandial serum glucose, insulin, IGF-1 and IGFBP-3 in a randomized, controlled feeding study That is a modest shift, but it suggests that the overall pattern of your diet, not just how much protein you eat, contributes to where your IGF-1 lands.
The Cancer Connection
This is the area that gets the most public attention. IGF-1 is fundamentally a growth-promoting hormone. When it binds to its receptor on a cell surface, it activates signaling cascades that drive cell proliferation, inhibit programmed cell death, and promote cell survival.9PubMed. IGF1 receptor signaling pathways Those are exactly the processes that cancer cells exploit to grow and resist treatment. Epidemiological studies have found associations between higher circulating IGF-1 and increased risk for several cancers, with colorectal, breast, and prostate cancers among the most studied.
The evidence does not mean that high IGF-1 directly causes cancer in the way that, say, a carcinogenic chemical causes mutations. Rather, elevated IGF-1 creates an environment more favorable to the growth of cells that have already acquired cancerous changes. This distinction matters because it helps explain why interventions that lower IGF-1 modestly, such as dietary changes, are being explored as potential risk-reduction strategies rather than cancer treatments per se.
Metabolic Effects and Insulin Resistance
The relationship between IGF-1 and metabolic health is not a simple “more is worse” story. A Danish population study found a U-shaped association: people with both low and high IGF-1 levels had higher odds of insulin resistance compared to those in the middle range. Those in the lowest group had about 65% higher odds of elevated insulin resistance markers, while those in the highest group had roughly double the odds, compared to people with intermediate levels.10PubMed Central. The association between IGF-I and insulin resistance: a general population study in Danish adults
This U-shaped pattern is a recurring theme in IGF-1 research and is one of the reasons that interpreting your own levels is not straightforward. A level at the very top of the normal range might carry different metabolic implications depending on your age, body composition, and whether you have liver disease or another condition that alters IGF-1 metabolism. The “sweet spot” of moderate IGF-1 levels seems to be where the metabolic benefits outweigh the risks.
Heart and Blood Vessels
In the cardiovascular system, IGF-1 has both protective and harmful potential depending on context. At moderate levels, it supports vascular health and has anti-inflammatory properties. But in people with hypertension, elevated circulating IGF-1 has been linked to structural changes in the heart and blood vessels, including thickening of the heart’s left ventricle and remodeling of artery walls.11PubMed Central. New insights on the cardiovascular effects of IGF-1 These are adaptive changes in the short term, but over years they can contribute to heart failure and stiff arteries. In acromegaly patients, cardiovascular disease is one of the leading causes of reduced life expectancy, underscoring what happens when IGF-1 stays high for a long time.
Muscle, Bone, and Physical Function
If the cancer and cardiovascular data make IGF-1 sound purely dangerous, the musculoskeletal data provide an important counterbalance. IGF-1 directly promotes muscle protein synthesis and bone mineralization. A community study of middle-aged and older adults in Taiwan found that higher serum IGF-1 was independently associated with greater muscle mass, higher bone mineral density, and stronger handgrip performance in both men and women.12PubMed. Association Among Serum Insulin-Like Growth Factor-1, Frailty, Muscle Mass, Bone Mineral Density, and Physical Performance Among Community-Dwelling Middle-Aged and Older Adults in Taiwan IGF-1 also mediates the crosstalk between muscle and bone, meaning that gains in one tissue can reinforce gains in the other through mechanical and hormonal feedback.13PubMed Central. Role of IGF-I signaling in muscle bone interactions
This is part of why falling IGF-1 with age is considered a contributor to sarcopenia and osteoporosis, and why some researchers have explored whether boosting IGF-1 could slow those processes. The trade-off, of course, is the cancer-promoting potential discussed earlier, which makes any therapeutic use of IGF-1 a careful balancing act.
Brain Health and Cognitive Function
IGF-1 and its receptors are widely distributed throughout the central nervous system, where the hormone supports neuronal growth, synaptic plasticity, and the formation of new neurons in adulthood.14PubMed Central. Identification of the molecular mechanism of insulin-like growth factor-1 (IGF-1): a promising therapeutic target for neurodegenerative diseases associated with metabolic syndrome IGF-1 also appears to protect neurons against damage from excitotoxicity, the kind of harmful overactivation of nerve cells that occurs during stroke, brain trauma, and neurodegenerative diseases. Rodent studies have shown improvements in both brain pathology and behavior when IGF-1 was administered after these injuries.15PubMed Central. Research Progress on Neuroprotection of Insulin-like Growth Factor-1 towards Glutamate-Induced Neurotoxicity
In humans, a long-term prospective study of aging adults found that among men, higher IGF-1 levels were associated with a substantially lower risk of developing mild cognitive impairment or dementia over five years.16PubMed Central. Neuroprotective biomarkers and cognitive function in a long-term prospective population-based study of aging U.S. adults The neuroprotective story adds yet another layer to the challenge of interpreting IGF-1 levels: what might be protective for the aging brain could, at the same extreme, be growth-promoting for a dormant tumor.
The Longevity Paradox
Some of the most provocative data on IGF-1 come from animal studies on aging. Mice that are genetically deficient in growth hormone, and therefore have very low IGF-1, live significantly longer than normal mice, despite being smaller and less fertile.17PubMed Central. Somatotropic signaling: trade-offs between growth, reproductive development, and longevity The pattern extends across several species: reduced growth hormone and IGF-1 signaling is one of the most consistent predictors of extended lifespan in laboratory animals.
Whether this translates to humans is far less clear. People with very low IGF-1 due to genetic conditions like Laron syndrome appear to be protected from cancer, but they also have reduced stature and face other health challenges. Meanwhile, older adults with falling IGF-1 levels are the ones most vulnerable to frailty, cognitive decline, and fractures. The longevity field is still wrestling with this tension: the signaling pathway that helps you grow and repair tissue when you are young may be the same one that accelerates aging-related diseases when it stays active in later life. There is no clear consensus yet on what an “optimal” IGF-1 level looks like across a human lifespan.
IGF-1 During Pregnancy
Maternal IGF-1 rises naturally during pregnancy and plays a central role in fetal growth. It does this partly by acting on the mother’s own metabolism, increasing nutrient availability, and partly by acting directly on the placenta to enhance nutrient transport to the fetus.18PubMed Central. The neglected role of insulin-like growth factors in the maternal circulation regulating fetal growth When this system malfunctions in either direction, problems follow. In pregnancies complicated by fetal growth restriction, maternal IGF-1 tends to be low while binding proteins that sequester it are elevated, effectively starving the placenta of growth signals.19PubMed. Fetal and maternal plasma insulin-like growth factors and binding proteins in pregnancies with appropriate or retarded fetal growth
Gestational diabetes presents the opposite pattern. Higher maternal IGF-1 and lower IGFBP-1 increase the size and metabolic activity of the placenta, ramping up amino acid and glucose transport and contributing to fetal overgrowth, or macrosomia.20World Journal of Advanced Research and Reviews. Maternal, placental, and fetal Insulin-Like Growth Factor-I (IGF-1) and IGF Binding proteins (IGFBPs) in Diabetic pregnancies: Effects on fetal growth and birth size Both extremes carry obstetric risks, highlighting that tightly regulated IGF-1 is as important during pregnancy as it is at any other stage of life.
Lowering IGF-1 Through Diet and Fasting
Given the associations with cancer and metabolic risk, a practical question many people have is whether it is possible to deliberately lower IGF-1. The evidence suggests the answer depends on how aggressive the intervention is. A meta-analysis of randomized controlled trials found that energy restriction diets in general did not reliably reduce IGF-1. But fasting regimens did produce a significant drop, and caloric restriction of 50% or more of daily intake also worked.21PubMed. The influence of fasting and energy restricting diets on IGF-1 levels in humans: A systematic review and meta-analysis Moderate caloric restriction, the kind most people can sustain, was not enough on its own.
A dietary intervention study in women carrying BRCA mutations, who are at elevated breast cancer risk, tested a largely plant-based diet that reduced animal product consumption. The intervention group had significantly lower IGF-1 and a lower IGF-1 to IGFBP-3 ratio, along with reductions in weight, fat mass, and triglycerides. The drop in IGF-1 tracked specifically with the reduction in animal products consumed.22PubMed Central. A Dietary Intervention to Lower Serum Levels of IGF-I in BRCA Mutation Carriers This fits with the broader evidence that animal protein, especially dairy, is the strongest dietary driver of IGF-1.
Why IGF-1 Test Results Can Be Confusing
If you have had your IGF-1 levels tested, you may have found interpreting the number harder than expected. Part of the problem is that different laboratories use different assays, different reference ranges, and different ways of converting results into standardized scores. A study of Dutch laboratories found that even when labs used the same calibration sample, converting raw numbers into standardized scores introduced substantial variability, meaning the same blood sample could yield different interpretations depending on which lab processed it.23PubMed. IGF-1 as screening tool for acromegaly and adult-onset growth hormone deficiency in the Netherlands Binding proteins in your blood can also interfere with certain types of IGF-1 assays, and mass spectrometry-based methods are gradually being adopted to improve accuracy, but they are not yet universal.24PubMed. Challenges of insulin-like growth factor-1 testing
Normal ranges also shift dramatically with age and sex. IGF-1 peaks during puberty, when it can be several times the adult level, then gradually declines for the rest of life. A value that would be unremarkable in a teenager might be flagged as elevated in a 60-year-old. If your doctor orders an IGF-1 test, the result needs to be interpreted in the context of your age, sex, nutritional status, and liver function, not just compared to a single cutoff.
IGF-1 Receptor Crosstalk in Thyroid Eye Disease
One of the more surprising recent developments in IGF-1 research involves its receptor’s role in thyroid eye disease, the condition that causes bulging eyes and eye pain in some people with Graves’ disease. The IGF-1 receptor on orbital fibroblasts, the connective tissue cells behind the eye, physically interacts with the TSH receptor, and autoantibodies that target the TSH receptor in Graves’ disease can also activate the IGF-1 receptor. When both receptors are activated simultaneously, the result is a synergistic increase in cell proliferation and inflammation that exceeds what either receptor would produce alone.25PubMed Central. It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease26PubMed Central. Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition
This discovery has already led to a treatment. Teprotumumab, a monoclonal antibody that blocks the IGF-1 receptor, was approved for thyroid eye disease and has shown the ability to reduce eye protrusion. It is a vivid example of how IGF-1 signaling extends into territories that, at first glance, seem unrelated to growth.
Athletic Misuse and the Risks of Exogenous IGF-1
Because IGF-1 promotes muscle growth and recovery, it has become a target for doping in competitive and recreational sports. Athletes sometimes self-administer recombinant IGF-1 or use growth hormone to raise IGF-1 levels indirectly. The risks of doing so mirror the complications of acromegaly, including joint problems, organ enlargement, and metabolic disruption. A particular danger of injecting IGF-1 directly is severe hypoglycemia, because the hormone can drive blood sugar dangerously low at pharmacological doses.27PubMed Central. Growth hormone, IGF-I and insulin and their abuse in sport Unlike testosterone or erythropoietin, there is little evidence that exogenous IGF-1 actually improves athletic performance in humans at tolerable doses, making the risk-benefit calculation especially poor.
IGF-1 Genetics and Body Size in Dogs
A fascinating window into how powerfully IGF-1 shapes biology comes from the domestic dog, the most size-variable mammal on the planet. A landmark genetics study identified a single variant near the IGF1 gene that was shared by virtually all small dog breeds and nearly absent in giant breeds.28PubMed Central. A single IGF1 allele is a major determinant of small size in dogs Later work refined this to a variant in a non-coding RNA that interacts with the IGF1 gene, controlling roughly 15% of the total body size variation across more than 200 breeds. The small-body allele turned out to be ancestrally old, present in ancient wolves and smaller wild canids, and was nearly lost during the Pleistocene before being resurrected by human selective breeding for small companion dogs.29PubMed Central. Natural and human-driven selection of a single non-coding body size variant in ancient and modern canids The fact that a single genetic region near IGF1 can account for the difference between a Chihuahua and a Great Dane speaks to the extraordinary leverage this hormone has on growth across species.